Accuray Incorporated (ARAY) Given Consensus Recommendation of “Hold” by Brokerages
Shares of Accuray Incorporated (NASDAQ:ARAY) have received a consensus rating of “Hold” from the seven brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $7.50.
ARAY has been the subject of several research analyst reports. Aegis reaffirmed a “buy” rating on shares of Accuray in a research report on Tuesday, March 21st. Zacks Investment Research raised shares of Accuray from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research report on Tuesday, April 4th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $7.00 price objective (down from $8.00) on shares of Accuray in a research report on Saturday, April 29th. Finally, BTIG Research reaffirmed a “hold” rating on shares of Accuray in a research report on Sunday, April 30th.
Accuray (NASDAQ ARAY) opened at 4.45 on Tuesday. Accuray has a 12 month low of $3.85 and a 12 month high of $6.39. The company’s 50-day moving average is $4.16 and its 200-day moving average is $4.82. The stock’s market capitalization is $369.35 million.
Accuray (NASDAQ:ARAY) last announced its quarterly earnings data on Thursday, April 27th. The medical equipment provider reported ($0.06) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.01 by $0.07. The company had revenue of $97.31 million during the quarter, compared to analysts’ expectations of $110.23 million. Accuray had a negative net margin of 8.61% and a negative return on equity of 61.49%. The business’s revenue for the quarter was down 7.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.01 earnings per share. Equities research analysts forecast that Accuray will post ($0.30) EPS for the current year.
Institutional investors have recently bought and sold shares of the company. RNC Capital Management LLC raised its position in Accuray by 5.0% in the first quarter. RNC Capital Management LLC now owns 27,500 shares of the medical equipment provider’s stock worth $131,000 after buying an additional 1,300 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in Accuray during the first quarter worth about $141,000. Goldman Sachs Group Inc. raised its position in Accuray by 116.3% in the first quarter. Goldman Sachs Group Inc. now owns 30,173 shares of the medical equipment provider’s stock worth $143,000 after buying an additional 16,223 shares in the last quarter. Advisory Services Network LLC acquired a new position in Accuray during the first quarter worth about $154,000. Finally, PEAK6 Investments L.P. acquired a new position in Accuray during the first quarter worth about $193,000. 84.24% of the stock is owned by institutional investors.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.